Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(12 sites)
China
Fujian Medical University Union Hospital, Fuzhou, Fujian Fujian Provincial Hospital Affiliated to Fuzhou University, Fuzhou, Fujian Affiliated Hospital of Putian University, Putian, Fujian Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Sanming First Hospital, Sanming, Fujian The First Affi liated Hospital of Xiamen University, Xiamen, Fujian Zhangzhou Affiliated Hospital to Fujian Medical University, Zhangzhou, Fujian Jiangxi Cancer Hospital, Nanchang, Jiangxi Shandong Cancer Hospital, Jinan, Shandong Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality Zhejiang Cancer Hospital, Hangzhou, Zhejiang The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Last updated December 2025